Oncolytics announces issuance of 2nd European patent.
Oncolytics Biotech, Inc. (Calgary, Canada) has been granted European Patent 1,309,672 entitled "Method of Producing Infectious Reovirus." The claims relate to a method of producing infectious mammalian reovirus which is suitable for clinical administration to mammals including humans."This patent is consistent with our strategy to continue to expand and strengthen our portfolio of intellectual property worldwide," said Dr. Matt Coffey, Chief Scientific Officer for Oncolytics. "Along with our clinical trial and collaborative research programs in Europe, the United States and Canada, these patents are a key component of our development strategy for REOLYSIN."
Oncolytics is a biotechnology company focused on the development of REOLYSIN, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, prostate, pancreatic, bladder and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that REOLYSIN was well tolerated and that the reovirus demonstrated activity in tumours injected with REOLYSIN.
Oncolytics Biotech, Inc.
+1-403-670-7377
www.oncolyticsbiotech.com
 Printer friendly
 Cite/link
 Email
 Feedback
| |
| Publication: | BIOTECH Patent News |
|---|---|
| Geographic Code: | 1CANA |
| Date: | Aug 1, 2005 |
| Words: | 200 |
| Previous Article: | Sigma-Aldrich licenses fundamental RNAi patent estate from Alnylam. |
| Next Article: | Alfred E. Mann Foundation obtains United States patent. |
| Topics: | |